Skip to main content

Advertisement

Log in

Intravenous Immunoglobulin and Rituximab for Cerebellar Ataxia with Glutamic Acid Decarboxylase Autoantibodies

  • Original Paper
  • Published:
The Cerebellum Aims and scope Submit manuscript

Abstract

Cerebellar ataxia associated with glutamic acid decarboxylase autoantibodies (GAD-ab) is a rare and usually slow progressive disease with moderate to severe gait and limb ataxia, dysarthria, and nystagmus. The treatment for this condition is still being discussed. We report the cases of three patients with GAD-ab cerebellar ataxia treated successively with intravenous immunoglobulin (IVIg) and rituximab. Symptoms improved in one case after rituximab therapy and were stabilized in another after a combined therapy of IVIg and rituximab. The third patient continued to worsen despite these treatments. We conclude that IVIg and rituximab therapy could improve or stabilize GAD-ab cerebellar ataxia. Early treatment, the lack of cerebellar atrophy on magnetic resonance imaging, and a subacute onset of the symptoms could be decisive prognostic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–63.

    Article  PubMed  Google Scholar 

  2. Nanri K, Niwa H, Mitoma H, Takei A, Ikeda J, Harada T, et al. Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum. 2013;12(2):171–5.

    Article  CAS  PubMed  Google Scholar 

  3. Abele M, Weller M, Mescheriakov S, Bürk K, Dichgans J, Klockgether T. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology. 1999;52:857–9.

    Article  CAS  PubMed  Google Scholar 

  4. Pedroso JL, Braga-Neto P, Dutra LA, Barsottini OG. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy. Arq Neuropsiquiatr. 2011;69:993.

    Article  PubMed  Google Scholar 

  5. Lauria G, Pareyson D, Pitzolu MG, Bazzigaluppi E. Excellent response to steroid treatment in anti-GAD cerebellar ataxia. Lancet Neurol. 2003;2:634–5.

    Article  PubMed  Google Scholar 

  6. McFarland NR, Login IS, Vernon S, Burns TM. Improvement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia. Neurology. 2006;67:1308–9.

    Article  PubMed  Google Scholar 

  7. Bonnan M, Cabre P, Olindo S, Signate A, Saint-Vil M, Smadja D. [Steroid treatment in four cases of anti-GAD cerebellar ataxia]. Rev Neurol (Paris). 2008;164:427–33.

    Article  CAS  Google Scholar 

  8. Awad A, Stüve O, Mayo M, Alkawadri R, Estephan B. Anti-glutamic acid decarboxylase antibody-associated ataxia as an extrahepatic autoimmune manifestation of hepatitis C infection: a case report. Case Rep Neurol Med. 2011;2011:975152.

    PubMed Central  PubMed  Google Scholar 

  9. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–6.

    Article  CAS  PubMed  Google Scholar 

  10. Fekete R, Jankovic J. Childhood stiff-person syndrome improved with rituximab. Case Rep Neurol. 2012;4:92–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Bacorro EA, Tehrani R. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab. J Clin Rheumatol. 2010;16:237–9.

    Article  PubMed  Google Scholar 

  12. Venhoff N, Rizzi M, Salzer U, Bossaller L, Thoden J, Eibel H, et al. Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study. Ann Rheum Dis. 2009;68:1506–8.

    Article  CAS  PubMed  Google Scholar 

  13. Mitoma H, Song SY, Ishida K, Yamakuni T, Kobayashi T, Mizusawa H. Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase. J Neurol Sci. 2000;175(1):40–4.

    Article  CAS  PubMed  Google Scholar 

  14. Manto M-U, Laute M-A, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007;61:544–51.

    Article  CAS  PubMed  Google Scholar 

  15. Ishida K, Mitoma H, Wada Y, Oka T, Shibahara J, Saito Y, et al. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia. J Neurol Neurosurg Psychiatr. 2007;78:190–2.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Hampe CS, Petrosini L, De Bartolo P, Caporali P, Cutuli D, Laricchiuta D, et al. Monoclonal antibodies to 65 kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet J Rare Dis. 2013;8:82.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Chang T, Alexopoulos H, McMenamin M, Carvajal-González A, Alexander SK, Deacon R, et al. Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 2013;doi:10.1001

  18. Cao BB, Huang Y, Lu JH, Xu FF, Qiu YH, Peng YP. Cerebellar fastigial nuclear GABAergic projections to the hypothalamus modulate immune function. Brain Behav Immun. 2013;27(1):80–90.

    Article  CAS  PubMed  Google Scholar 

  19. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67:1068–70.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Patient Consent

The patients' explicit consent was obtained before publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vincent Planche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Planche, V., Marques, A., Ulla, M. et al. Intravenous Immunoglobulin and Rituximab for Cerebellar Ataxia with Glutamic Acid Decarboxylase Autoantibodies. Cerebellum 13, 318–322 (2014). https://doi.org/10.1007/s12311-013-0534-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12311-013-0534-3

Keywords

Navigation